Clinical Study
Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients
Table 3
Pearson’s correlation coefficient (
) between the cumulative dose and treatment duration and the OCT parameters in the study group.
| OCT | Cumulative dose in grams | Treatment duration in years |
| CFT | −0.013 (p value = 0.936) | −0.017 (p value = 0.918) | Parafoveal thickness | | | Superior | −0.134 (p value = 0.409) | −0.135 (p value = 0.405) | Inferior | −0.048 (p value = 0.770) | −0.048 (p value = 0.768) | Nasal | 0.075 (p value = 0.644) | 0.074 (p value = 0.649) | Temp. | −0.188 (p value = 0.247) | −0.189 (p value = 0.244) | Perifoveal thickness | | | Superior | −0.065 (p value = 0.689) | −0.068 (p value = 0.678) | Inferior | −0.259 (p value = 0.107) | −0.260 (p value = 0.105) | Nasal | 0.086 (p value = 0.598) | 0.084 (p value = 0.605) | Temp. | −0.253 (p value = 0.115) | −0.256 (p value = 0.111) | RNFL | −0.119 (p value = 0.464) | −0.120 (p value = 0.462) | GCC thickness | −0.003 (p value = 0.984) | −0.002 (p value = 0.989) | FLV | 0.056 (p value = 0.730) | −0.055 (p value = 0.736) | GLV | 0.114 (p value = 0.483) | −0.114 (p value = 0.482) |
|
|